We explored diverse alterations contributing to liposarcomagenesis by sequencing the genome, exome, transcriptome, and cytosine methylome of a primary and recurrent dedifferentiated liposarcoma (DLPS) from distinct chemotherapy/radiotherapy-naïve patients. The liposarcoma genomes had complex structural rearrangements, but in different patterns, and with varied effects on the structure and expression of affected Research.
Introduction
Liposarcoma is the most common soft-tissue sarcoma (~20% of all adult sarcomas).
Dedifferentiated liposarcoma (DLPS) is a heterogeneous subtype that is particularly aggressive in the retroperitoneum (1) . Excisional surgery remains the standard of care for localized DLPS, but ~80% of patients diagnosed with primary retroperitoneal DLPS will die from locally recurrent or metastatic disease within five years. As these tumors are largely resistant to conventional cytotoxic therapies, it is imperative to identify novel therapeutic targets for this disease. Here, we performed 16 concurrent massively parallel sequencing experiments in four samples, a primary and a local recurrence of DLPS and their paired non-neoplastic adipose tissue controls from two unrelated individuals, male and female (hereafter referred to as DLPS1 and DLPS2 respectively). These samples were selected from a large panel of molecularly characterized retroperitoneal DLPS of similar clinical and pathologic characteristics (Table S1 ). Initial array-based DNA copy number profiling was performed long-insert mate-paired whole-genome sequencing (~5x coverage), exome sequencing (~30-70x coverage), RNA sequencing of the poly(A)+ transcriptome, and finally an enrichment of methylated DNA followed by sequencing (Fig. S2 ). Integrative analyses were complemented by analysis of selected mutations, methylation, and expression changes in larger sets of tumor and normal samples, and by assessing the functional significance of specific aberrant methylation by pharmacological inhibition both in vitro and in an accompanying animal model of DLPS.
Results

Structural rearrangement in liposarcoma
We identified 355 and 543 somatically acquired genomic rearrangements (intra-and inter-chromosomal) in DLPS1 and DLPS2 respectively, from mate-paired sequencing reads that aligned atypically to the genome (Table S2 , estimated false discovery rate (FDR) of 8.7%; see Supplementary Methods). In these genomes, genomic amplification at one or both breakpoints was the source of nearly all rearrangements, including 94.6% in the primary DLPS1, and all but three (99.4%) in the recurrent DLPS2 (all involving chr9 sequence). These patterns are fundamentally different from those observed in breast or pancreatic cancers (4, 5) , in which a greater fraction of rearrangements are associated with tandem duplication or deletion than genomic amplifications, though variability exists. Despite the common origin of most rearrangements found here, their pattern between these tumors was markedly different. Although chromosome 12 amplifications were prominent in both tumors and were the primary source of structural abnormality DLPS1, the recurrent DLPS2 had a less complex 12q amplicon, but greater diversity of inter-chromosomal rearrangements (Fig. 1A-B) .
The instability of the 12q locus in DLPS1 was noteworthy. The greater amplicon spanned ~44Mb of the q-arm and showed a complex network of back-and-forth intrachromosomal rearrangements in both inverted and non-inverted orientation (Fig.   1C ). Three clusters of rearrangement were apparent and suggest a model of amplicon evolution that started with an initial co-amplification of CDK4 and MDM2 (albeit in distinct events) incorporating sequence from focal copy number amplifications of 3q11.2 and 20p12.3 respectively. This was cleaved out and replicated autonomously and unstably, likely acquiring the additional intra-chromosomal rearrangements sporadically over late cell cycles. While the clustering of rearrangements was distinct, and the systematic remodeling of chromosome 12 profound, its origin is unlikely to be a chromothripsis, a single cellular catastrophe posited to drive a subset of osteosarcomas or chordomas (6) . The 12q structure in DLPS1 lacks many of the hallmarks of chromothripsis, such as cycling between discrete copy number states and retained heterozygosity (inferred from 250K SNP array data (3) and heterozygous SNPs in the whole-genome sequence data). The 12q structure in both DLPS1 and DLPS2 instead likely resulted from progressive rearrangement and amplification. Additionally, while retrotransposition of mobile elements (principally L1 and Alu) is a natural source for structural mutagenesis in human genomes (7, 8) , none of the rearrangement breakpoints detected in either genome corresponds to known insertion polymorphisms (dbRIP release 2, ref. (9)) or those recently found in lung tumors (10 generate long contigs, confirming the complex interspersed pattern of the amplicon indicated by spectral karyotyping of DLPS cell lines (data not shown).
In total, 64% of rearrangements affected the sequence of protein-coding or noncoding genes (compared to ~56% expected by chance, p-value<10 -4 ; Supplementary Methods). These were diverse in pattern. Notable events included internal rearrangements and translocations involving HMGA2 in both DLPS genomes ( Fig. 2A) .
High mobility group A2 (HMGA2) is a non-histone, chromatin-associated protein that lacks transcriptional activity, but regulates transcription in trans by altering chromatin architecture (11) . Rearrangements involving HMGA2 on 12q are recurrent in DLPS, with whole-gene HMGA2 amplifications and a 5' amplification with a breakpoint between exon 5 and the 3' untranslated region (UTR) of the long isoform each affecting ~30% of tumors (3). The primary tumor (DLPS1) harbored the latter complex 5' amplicon, so we examined its structure and transcriptional consequences in detail. This amplicon included the full HMGA2 open reading frame (ORF), which was fused to intergenic chromosome 12 sequence ( Fig. 2A, top) . This structure was confirmed by concurrent RNA sequencing with splice junction reads indicating that only the long isoform was expressed and that it lacked its 3' UTR ( Fig. 2A, bottom) . RNA sequence data confirmed that HMGA2 was strongly over-expressed in DLPS1, though not in DLPS2 ( Fig. 2A, inset) , which had an internal intron 3 amplicon clustering in a position similar to fusion-associated rearrangements in benign lipomas (11) , though here it lacked a fusion partner. In DLPS1, the structure and over-expression of HMGA2 suggest that the rearrangement eliminated microRNA repression of the gene mediated by let7 binding to For those DNA rearrangements that juxtaposed two genes into a putative novel ORF, we used RNA sequencing data to explore the candidate fusion junctions and identified seven acquired chimeric fusion transcripts, of which five (71%) validated with RT-PCR of RNA across the rearranged exon-exon junction (Table S3 and Fig. S3 ; see Supplementary Methods). While in some cases highly expressed, as with the RCOR1-WDR70 out-of-frame fusion (Fig. 2B) , studying additional cases is necessary to determine if these are actually passenger events, given the extensive genome remodeling in these two sarcomas. This large burden of rearrangements will, by chance, affect the coding regions of many genes, among which a minority will result in expressed gene fusions. Indeed, the scarcity of expressed fusions in these genomes on a background of systematic rearrangement may indicate instead that the primary driver of 12q amplification in DLPS tumors is the dosage increases to a large number of genes. Nevertheless, our current analysis confirms the value of cross-validating DNA rearrangements with concurrent RNA sequencing to identify expressed fusions.
The nucleotide mutational landscape
To determine somatic nucleotide substitutions in these tumors, we combined the results of RNA sequencing with those of exome capture and DNA sequencing in both tumors and matched normal samples. We identified 8 and 13 confirmed somatic mutations in the two tumors respectively after obtaining independent validation data with deep 454 sequencing on a subset of candidate mutations (Table S4; Methods). This is equivalent to ~0.53 tumor-specific mutations per million bases, a modest point mutation burden similar to our previous findings using limited Sanger sequencing of selected candidate genes (3). In fact, while the patterns of structural rearrangement between the primary and local recurrence were very different ( Fig. 1A-B ), the point mutation rate and the nucleotide context of the mutations were similar.
Exome sequencing also captured a significant fraction of the whole-gene and intragenic copy-number alterations apparent in the whole-genome sequencing data (Fig. S4 ), as has previously been observed with targeted approaches (13) . (Table S4 ; in addition to rediscovering the four mutations in the originally sequenced samples). None of the mutations among the 94 additional liposarcomas were identical to those originally described. Nevertheless, the frequency, diversity, and predicted functional impact of the HDAC1 mutations (Table S4) identified here is noteworthy, and is consistent with the emergence of mutations in key epigenetic or chromatin machinery in multiple human cancer types.
In addition to the coding point mutations and small insertions and deletions described here, liposarcoma transcriptomes were altered in diverse ways. We confirmed two somatic mutations in DLPS2 in the 3' UTRs of MAP3K4 (373T>C) and RAB11FIP2 (3879A>G) respectively (Table S4 ). These altered the seed sequence of predicted microRNA target sites (MAP3K4/miR-495 and RAB11FIP2/miR-155), and were consistent with elevated expression in the tumor (Fig. 2C, Supplementary Results). Differential allele-specific expression (ASE) between normal and tumor transcriptomes was also apparent (Table S5 ) and its origins could be traced with concurrent DNA sequencing, as in the case of three genes on or adjacent to the CDK4 amplicon on 12q13.3-14.1 (GEFT, OS9, and METTL1) all with ASE resulting from a single allele-specific copy number amplification ( 
CEBPA is frequently methylated in DLPS
To investigate cell-type and tumor-specific DNA methylation patterns, we generated ~62 million uniquely aligned reads [3.1 gigabases (Gb)] in the matched tumor and normal samples with an MBD-based enrichment protocol (14) (see Methods). From peaks of methylation generated from read distributions, we found that global patterns of cytosine methylation were similar between each tumor and normal and between the two patients ( Fig. S5-7 ). After normalizing methylation levels by the tumor's intrinsic copy number inferred from whole-genome sequencing (Fig. S8-9 ), we identified persistently In total, 833 DMRs originated from the canonical promoters of 677 genes. RNA sequencing indicated that 175 of these genes were expressed in the normal adipose samples and differentially expressed (≥ 2-fold) in the affected tumor. Noteworthy among these were multiple effectors of adipocyte differentiation: GATA2, KLF4, and CEBPA.
While GATA2 was among the most hypo-methylated genes, GATA2 mRNA levels were not induced despite its proven role as an anti-adipogenic factor. KLF4 plays a vital role in multiple differentiated pathways, including adipogenesis, through its early regulation of C/EBPβ, and is among a set of genes whose expression reprograms somatic cells to acquire pluripotency. Promoter methylation reduced KLF4 expression in both tumors (Fig. 3B-C 
Treating DLPS cells (the DDLS8817 cell line) with the DNA methyltransferase inhibitor 5-Aza-2'-deoxycytidine (5-aza; decitabine) reduced CEBPA promoter methylation levels by 30-50% (Fig. S10A) . While no further reduction was observed after the addition of histone deacetylase inhibitor SAHA, expression levels were induced 3-and 19-fold respectively (with 5-aza alone and in combination with SAHA), confirming a synergistic effect of de-methylation and the release of transcriptionally repressive chromatin (Fig. S10B) . More so than either compound alone, the combination of 5-aza and SAHA also substantially induced anti-proliferative and pro-apoptotic effects in DLPS cells in vitro and led to increased expression of early, intermediate, and late differentiation markers (Fig. 3E) , confirming reactivation of the differentiation pathway.
Finally, the combination of 5-aza and SAHA produced a significant reduction in DLPS tumor volume in vivo (Fig. 3E) . We therefore propose that CEBPA methylation is common in DLPS, contributes in part to the adipogenic block in tumors that lack JUN amplification-driven C/EBPβ disruption (17) , and is an important step in the progression of well-differentiated to dedifferentiated liposarcomas.
Epigenetic regulation of small RNAs in high-grade DLPS
While conventional methylation profiling focuses on CpG-rich regulatory regions of the genome, unbiased genome-wide methylation sequencing can identify epigenetic control of additional genomic features. Indeed, the regulation of small RNAs by methylation has emerged as a mechanism in cancer, but has been investigated predominantly in a microRNA-specific manner (18), or has been measured indirectly (19) . Here, we identified 13 microRNAs whose putative promoters were differentially methylated (data 
not shown). Notably, a peak of methylation spanned the putative promoter of miR-193b on 16p13.12 in the 3' shore of an adjacent CpG island in DLPS1, but this methylation was lacking from its matched normal sample (q-value = 1.1x10 -13 , Fig. 4A-B) . While microRNA promoters are less well characterized than their protein-coding counterparts, this locus has significant H3K4me3 enrichment, a histone modification that marks active promoters, in multiple human lineages (20, 21) (Fig. 4B) . To test whether increased promoter methylation silenced miR-193b in this tumor, we explored miR-193b expression with small RNA sequencing in this sample and a larger cohort of normal adipose tissue, WLPS, and DLPS tumors (n=58, ref. (22)). This confirmed that miR193b expression was selectively lower in DLPSs (p-value < 10 -8
, Fig. 4C ). Among WLPSs, miR-193b expression levels were similar to those of normal adipose tissue, indicating that loss of miR-193b expression is a late event in liposarcoma progression.
To explore the possibility that methylation was responsible for the reduction of miR193b in this larger cohort, we performed pyrosequencing of bisulfite-converted DNA in the region representing the peak of methylation from DLPS1. In a panel of WLPS and DLPS tumors for which small RNA sequencing data were available, we found that as the percent methylation increased in this region, miR-193b expression was reduced, and this was specific to DLPSs (R = -0.76, p-value = 0.0004; Fig. 4D ). To further explore the effect of epigenetic silencing of miR-193b, we characterized the expression changes of its predicted targets. Predicted gene targets of miR-193b were determined with miRanda-mirSVR (23) and included only those highly conserved target sites with a seed match length of ≥7bp. We examined their global expression changes in WLPS and DLPS compared to normal adipose tissue samples respectively. In DLPS tumors in which miR-193b is silenced by methylation, genes with predicted targets sites for miR193b were significantly upregulated compared to normal adipose tissue, an effect we did not observe in well-differentiated tumors, which have normal miR-193b levels (one sided Kolmogorov-Smirnov p-value = 1.45x10 -6 ; Fig. 4E ). These data indicate miR-193b is silenced by methylation selectively in aggressive disease and this silencing broadly affects the expression of its putative targets. This finding also hints at the broader possibility of systematic epigenetic control of small RNAs in cancer genomes and specifically their effect in liposarcomagenesis.
Discussion
Here we report the concurrent sequencing of human tumor genomes, exomes, transcriptomes, and cytosine methylomes, the results of which were integrated to yield a picture of genomic alterations in a primary and a locally recurrent liposarcoma. While these tumors harbored abnormalities at all levels, the structural remodeling of liposarcoma genomes was profound and had varied effects on their transcriptomes.
Exome sequencing revealed a modest point mutation rate in these tumors, yet uncovered for the first time genes recurrently mutated in this subtype of soft-tissue sarcoma (HDAC1, MAPKAP1, PTPN9, and DAZAP2). Also, this first portrait of liposarcoma methylomes indicates that aberrant methylation has broad effects tied closely to differentiation phenotypes and suggests a role for demethylating agents in the treatment of DLPS tumors.
The prevalence of CEBPA methylation found here, as well as its specificity and clonality in DLPS, raises interesting questions about the dysregulation of adipogenesis (17) . While the adipogenic block is common to all DLPS tumors, we and others observed JUN genomic amplification and over-expression in only ~24% of cases (3) (though in the absence of amplification, JUN may also be overexpressed via upstream kinase-driven activation). Moreover, recent evidence indicates that activated JUN, while oncogenic in DLPS cells, is not sufficient to block adipocytic differentiation, implying alternative abnormalities are necessary (24) . We speculate that the CEBPA promoter methylation identified here may uncouple CEBPA expression from C/EBPβ-mediated induction and therefore may play a role in at least some of the unexplained adipogenic block in DLPS.
The relationship between CEBPA methylation and the HDAC1 mutations discovered here is unknown. The histone deacetylase activity of HDAC1 targets promoters and blocks transcription, and although the loss of HDACs can enhance adipogenesis (25, 26) , this is not true in all contexts (27) . Also, HDAC1 specifically sequesters and represses the C/EBPα promoter, and PPARγ is necessary to release C/EBPα expression (28) . These data, in combination with our finding of both KLF4 and CIDEA methylation (data not shown) suggests the possibility of a series of alterations necessary to mediate different aspects of the adipogenic block in these tumors.
Other pathways and non-adipogenic phenotypes are likely also involved in the progression of well-differentiated liposarcomas to de-differentiated disease, and our finding of miR-193b methylation and silencing specific to aggressive disease implies an important role for aberrant expression of small RNAs in liposarcomagenesis. A role for miR-193b in cancer has been proposed based on its reduced expression in both hepatocellular carcinoma and melanoma (29, 30) , and recent evidence suggests miR193b is epigenetically silenced in prostate cancer (31) . While the validated miR-193b targets CCND1 and ETS1 were over-expressed in some of these malignancies (29, 30) , expression analysis of liposarcomas with and without miR-193b methylation indicated that neither gene is elevated in a DLPS-specific manner, as might be expected for miR193b loss. However, because CCND1 regulates CDK4 activity, and CDK4 is amplified in ~90% of DLPSs, upregulation of CCND1 due to miR-193b loss might be functionally redundant. This is confirmed by its lack of induction in DLPS tumors harboring miR- This work represents an initial integrated sequence analysis of liposarcoma, and while most non-coding sequence is insufficiently covered by these experiments, the depth and breadth of alterations revealed here indicates the somatic complexity of cancers is still under-appreciated. These data also reveal an unanticipated role for epigenetic abnormalities in dedifferentiated liposarcoma and the potential therapeutic importance of demethylating agents for treating liposarcomas.
Research. (14). This MBD affinity-purification assay is selective for methylated CpGs and suitable for massively parallel sequencing.
Materials and Methods
Patient
MBD-enriched fragment libraries were prepared and run in either quad or octet format on a SOLiD 3 instrument. The small RNA sequencing discussed here was performed on an Illumina Genome Analyzer II, and is described in greater detail elsewhere (22) . In all experiments, sequencing generated 50-mer dinucleotide reads in color space, and data were obtained from concurrent sequencing runs on the SOLiD 3 and 4 platforms. 
